<DOC>
	<DOCNO>NCT01744223</DOCNO>
	<brief_summary>This study evaluate patient blood cell cancer go allogeneic ( donor ) blood stem cell transplant partially match relative . The research study test whether immune cell , call T cell , come donor relative specially grown laboratory give back patient along stem cell transplant ( T cell addback ) , help immune system recover faster transplant . As safety measure , T cell `` program '' `` self-destruct switch '' , give patient , T cell start react tissue ( call `` graft versus host '' disease , GVHD ) , T cell destroy .</brief_summary>
	<brief_title>Safety Study Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant</brief_title>
	<detailed_description>This Phase1/2 dose escalation study evaluate safety feasibility BPX-501 infuse partially mismatch , relate ( haploidentical ) , T cell-depleted HSCT . The purpose clinical trial determine whether BPX-501 infusion facilitate engraftment , enhance immune reconstitution potentially improve graft versus leukemia ( GVL ) effect , potential reduce severity duration severe acute graft versus host disease ( GvHD ) . The trial evaluate treatment GvHD infusion dimerizer drug ( AP1903 ) subject present severe GvHD ( Grades III IV ) well subject Grade I II progress respond corticosteroid therapy within 4 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Lack suitable conventional donor ( i.e . 7/8 8/8 related 7/8 8/8 unrelated donor ) presence rapidly progressive disease permit time identify unrelated donor HLA typing perform high resolution ( allele level ) HLAA , B , Cw , DRBl , locus . A minimum match 5/10 require . The donor recipient must identical , determine high resolution typing , least one allele follow genetic locus : HLAA , HLAB , HLACw , HLA DRB1 . Subjects adequate physical function measure : ) Cardiac : Left ventricular ejection fraction rest must &gt; 35 % , shorten fraction &gt; 25 % . b ) Hepatic : Bilirubin &lt; 2.5 mg/dL ; ALT , AST , Alkaline Phosphatase &lt; 5 x ULN . c ) Renal : Serum creatinine within normal range age , creatinine clearance GFR &gt; 40 mL/min/1.73m2 . ) Pulmonary : FEV 1 , FVC , DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; 02 saturation &gt; 92 % room air . Clinical Diagnosis one following : Acute Lymphoblastic Leukemia , Acute Myelogenous Leukemia , Lymphoma Subjects must receive cytotoxic chemotherapy within 3 month consent date ( measure start date chemotherapy ) . Performance status : Karnofsky/Lansky score &gt; 60 % . HLAmatched , relate 7or 8/8 allele match ( HLAA , B , Cw , DRBl ) unrelated donor able donate . Autologous hematopoietic stem cell transplant &lt; 3 month prior enrollment . Pregnancy breastfeed . Evidence HIV infection know HIV positive serology . Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) . Nonhematologic malignancy within prior three ( 3 ) year . Prior allogeneic hematopoietic stem cell transplant . Subjects history primary idiopathic myelofibrosis . Bovine product allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>iCaspase9</keyword>
	<keyword>iCasp9</keyword>
	<keyword>Inducible Caspase</keyword>
	<keyword>AP1903</keyword>
	<keyword>Dimerizer drug</keyword>
	<keyword>T deplete</keyword>
	<keyword>Suicide gene</keyword>
	<keyword>CD-34 selection</keyword>
	<keyword>haplotransplantation</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Allogenic transplantation</keyword>
</DOC>